iRadimed (NASDAQ:IRMD) Sees Large Volume Increase Following Earnings Beat

iRadimed Corporation (NASDAQ:IRMD) saw an uptick in trading volume on Friday after the company announced better than expected quarterly earnings. Approximately 172,292 shares were traded during trading, an increase of 63% from the previous session’s volume of 105,746 shares.The stock last traded at $94.3770 and had previously closed at $95.21.

The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The firm had revenue of $20.47 million for the quarter, compared to analysts’ expectations of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Investors of record on Friday, August 14th will be paid a dividend of $0.20 per share. The ex-dividend date is Friday, August 14th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is 43.72%.

Key iRadimed News

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, iRadimed has an average rating of “Buy” and an average price target of $120.00.

Insiders Place Their Bets

In other news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $87.51, for a total value of $437,550.00. Following the transaction, the chief executive officer owned 2,175,000 shares in the company, valued at $190,334,250. This represents a 0.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 21,250 shares of company stock worth $1,836,403. Insiders own 34.60% of the company’s stock.

Institutional Trading of iRadimed

Several hedge funds and other institutional investors have recently modified their holdings of IRMD. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of iRadimed during the 2nd quarter worth about $217,000. The Manufacturers Life Insurance Company grew its stake in iRadimed by 48.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 3,933 shares of the medical equipment provider’s stock valued at $379,000 after buying an additional 1,284 shares during the last quarter. Quantinno Capital Management LP lifted its position in shares of iRadimed by 12.5% during the 1st quarter. Quantinno Capital Management LP now owns 3,482 shares of the medical equipment provider’s stock worth $335,000 after purchasing an additional 387 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in shares of iRadimed by 15.4% during the first quarter. Lazard Asset Management LLC now owns 48,914 shares of the medical equipment provider’s stock worth $4,708,000 after buying an additional 6,524 shares during the last quarter. Finally, Aristides Capital LLC raised its stake in iRadimed by 8.5% during the 1st quarter. Aristides Capital LLC now owns 30,083 shares of the medical equipment provider’s stock valued at $2,896,000 after purchasing an additional 2,349 shares during the last quarter. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

iRadimed Price Performance

The company’s 50 day moving average is $94.54 and its two-hundred day moving average is $95.70. The firm has a market cap of $1.16 billion, a P/E ratio of 50.76 and a beta of 0.90.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.